RLS Global AB

RLS Global AB
About Us
Contacts
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company’s platform technology and its unique features will help many patients around the world. Read more at rls.global

Contacts

Roland Frösing

Acting CEO

+46 723 20 61 00
roland.frosing@rlsglobal.se

Torbjörn Sannerstedt

Acting CFO

+46 708 66 22 55
torbjorn.sannerstedt@rlsglobal.se

Quotes

The fact that ChloraSolv, with very good efficacy, now can be used on venous leg ulcers and diabetic foot ulcers is very positive, not only for the patients and relatives but also for healthcare and society as this patient group is connected with large healthcare costs.

Karin Fischer, CEO, RLS Global

We are pleased to receive a positive confirmation from Lloyd’s register that ChloraSolv satisfies all required technological requirements.

Karin Fischer, CEO of RLS Global

RLS now has a detailed plan with activities for bringing ChloraSolv to the European markets in a structured manner.

Karin Fischer, CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

ChloraSolv is regulatory approved in Kuwait for diabetic foot ulcers

Mon, May 31, 2021 08:00 CET

RLS Global AB has received regulatory approval for ChloraSolv regarding the treatment of diabetic foot ulcers in Kuwait. With this approval, RLS has established the first market presence in the Middle East, which is an important region for RLS. The prevalence of diabetes in the Middle East is very high and is expected to increase until 2045 according to the International Diabetes Federation*. In Kuwait, the prevalence in the population is 12,2 percent compared to 4,5 percent in Sweden.Kuwait is the first step in establishing RLS’ presence in the Middle East. RLS has established a

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Links

Quotes

ChloraSolv is regulatory approved in Kuwait for diabetic foot ulcers

Subscribe